Otonomy (OTIC)
NASDAQ:OTIC

Otonomy Stock Analysis & Ratings

Otonomy Stock Analysis Overview

Smart Score
3
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Otonomy stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

OTIC

OTIC Stock Stats

Previous Close$1.97
Open$1.95
Bid1.75 x 500
Ask2.3 x 1500
Today’s Range$1.91 - $1.9601
52-Week Range$1.14 - $5.73
Volume134.12K
Average Volume230.38K
Market Cap$109.39M
Beta1.76
P/E Ratio-2.4
EPS-0.82
Earnings DateMar 07, 2022

Company Description

Otonomy

Otonomy, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Weber
Employees
56
Website
www.otonomy.com
ISIN
US68906L1052
Address
4796 Executive Drive, San Diego, CA, 92121, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

OTIC FAQ

What was Otonomy’s price range in the past 12 months?
Otonomy lowest stock price was $1.14 and its highest was $5.73 in the past 12 months.
    What is Otonomy’s market cap?
    Otonomy’s market cap is $109.39M.
      What is Otonomy’s price target?
      The average price target for Otonomy is $5.50. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $5.50 ,the lowest forecast is $5.50. The average price target represents 184.97% Increase from the current price of $1.93.
        What do analysts say about Otonomy?
        Otonomy’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Otonomy’s upcoming earnings report date?
          Otonomy’s upcoming earnings report date is Mar 07, 2022 which is in 45 days.
            How were Otonomy’s earnings last quarter?
            Otonomy released its earnings results on Nov 10, 2021. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.005.
              Is Otonomy overvalued?
              According to Wall Street analysts Otonomy’s price is currently Undervalued.
                Does Otonomy pay dividends?
                Otonomy does not currently pay dividends.
                What is Otonomy’s EPS estimate?
                Otonomy’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Otonomy have?
                Otonomy has 56,680,000 shares outstanding.
                  What happened to Otonomy’s price movement after its last earnings report?
                  Otonomy reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went up 0.472%.
                    Which hedge fund is a major shareholder of Otonomy?
                    Among the largest hedge funds holding Otonomy’s share is RA Capital Management. It holds Otonomy’s shares valued at 3M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis